Listeria Monocytogenes Infections Treatment Market

Market Insights

This report on the global Listeria monocytogenes infections treatment market studies various drugs used for the treatment of Listeria monocytogenes infections along with pipeline analysis of upcoming potential drugs. According to the Centers for Disease Control and Prevention (CDC), Listeriosis, a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes, is an important public health problem in the United States. In addition, CDC estimates that approximately 1600 illnesses and 260 deaths due to Listeriosis occur annually in the United States. Thus, the drug pipeline of the Listeria monocytogenes infections treatment market comprises potential drugs which are more target-specific and possess innovative properties.

For the purpose of this study, the various infection types studied include bacteremia, meningitis, brain abscess, gastroenteritis, endocarditis, and others. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn and the respective CAGRs for 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for the Listeria monocytogenes infections treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). In addition, the report also covers qualitative information associated with the drugs under phases II and I of the clinical trials.

The geographic segmentation of the global Listeria monocytogenes infections treatment market is performed for North America, Europe, Asia Pacific, and the Rest of the world. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Listeria monocytogenes Infections Treatment Market Portaiture
2.2 Global Listeria monocytogenes Infections Treatment Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Listeria monocytogenes Infections Treatment Market: Market Dynamics and Outlook
3.1 Listeria monocytogenes Infections Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)

Chapter 4 Global Listeria monocytogenes Infections Treatment Market, By Type of Infection
4.1 Preface
4.2 Bacteremia
4.3 Meningitis
4.4 Brain Abscess
4.5 Gastroenteritis
4.6 Endocarditis
4.7 Others
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Carbavance
4.8.1.2 Telavancin
4.8.1.3 Daptomycin
4.8.1.4 Prulifloxacin
4.8.1.5 DTaP-IPV/Hib combined vaccine
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Listeria Monocyogenes Infections Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
v.3.4 News Coverage
6.4 Astra Zeneca plc
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Sanofi SA
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Medimmune
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Baxter International, Inc.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG. 1 Global Listeria monocytogenes Infections Treatment Market, by Type of Infection, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Listeria monocytogenes Infections Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)
FIG. 5 Global Bacteremia Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 6 Global Meningitis Market of Listeria monocytogenes Infections Treatment, 20137– 2022 (USD Mn)
FIG. 7 Global Brain Abscess Market of Listeria monocytogenes Infections Treatment, 2013 –2022 (USD Mn)
FIG. 8 Global Gastroenteritis Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 9 Global Endocarditis Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 10 Global Others Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Carbavance Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Telavancin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Daptomycin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global Prulifloxacin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 15 Pipeline Analysis: Global DTaP-IPV/Hib combined vaccine Market for Listeria monocytogenes Infections , Upto 2022 (USD Mn)
FIG 16 Global U.S. Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 17 Global Canada Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 18 Global U.K Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 19 Global Germany Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 20 Global Rest of Europe Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 21 Global China Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Global Japan Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 23 Global Rest of Asia Pacific Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 24 Global Latin America Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 25 Global Middle East and Africa Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Listeria monocytogenes Infections Treatment Market Revenue, by Type of Infection, 2013 – 2022 (USD Mn)
TABLE 2 Global Listeria monocytogenes Infections Treatment Market Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia – Pacific Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Rest of the World Listeria monocytogenes Infections Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)